ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
Initial Public Offering generated gross proceeds of
net proceeds of
– Strong cash position of
–
Accelerated top-line data for P2b/3 randomized controlled study of izokibep in Hidradenitis Suppurativa (HS) from end of year, now anticipated in Q3 2023; Second confirmatory HS P3 trial now initiated and actively enrolling
Lonigutamab and SLRN-517 both now actively enrolling
in Phase 1/2 Proof-of-Concept Studies
LOS ANGELES, June 15, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the first quarter ended March 31, 2023, and highlighted additional recent corporate achievements.
“The past several months have been transformative for ACELYRIN. We continue to work toward our mission to develop clinically meaningful, differentiated medicines by executing on development plans to test our hypotheses and determine how our assets might best address the significant unmet need that remains for patients across a multitude of autoimmune and inflammatory diseases,” said Shao-Lee Lin, MD, PhD, founder and CEO, ACELYRIN. “I am particularly pleased for patients that in the past six months we have been able to share izokibep data demonstrating resolution of important manifestations of disease and significant evidence of positive impact on quality of life. With the proceeds of our recent initial public offering, we will continue to drive towards key value-driving milestones to deliver efficiently on our development plans. We are pleased today to be sharing the acceleration of timing for top-line pivotal data for izokibep in Hidradenitis Suppurativa (HS), now expected in the third quarter of 2023, and that a second confirmatory Phase 3 trial in HS is now actively enrolling.”
Recent Highlights and Upcoming Milestones
Initial Public Offering
On May 9, 2023, we closed our upsized initial public offering of 34,500,000 shares of common stock, which included the full exercise of the underwriters’ option to purchase up to 4,500,000 additional shares, at a price to the public of
Izokibep
In March, we shared as a late-breaking presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting data showing that treatment with izokibep led to high orders of HiSCR response at 12 weeks in the open label Part A of the Phase 2b/3 trial in HS. These responses included achieving HiSCR100, defined as complete resolution of abscesses and nodules with no new fistulae/draining tunnels, in moderate to severe patients representing both Hurley Stage II and III.
Part B of the Phase 2b/3 trial completed enrollment early and top-line results are now anticipated in Q3 2023. An independent Data Monitoring Committee (DMC) conducted a planned interim analysis, reported no safety concerns, and confirmed 160mg weekly (QW) as the dose for the second Phase 3 trial in HS. This Phase 3 trial is now actively enrolling.
In April, we announced 46-week data from the Phase 2 trial of izokibep in Psoriatic Arthritis (PsA) showing that continued treatment of 80mg every two weeks (Q2W) led to further improvements beyond 16 weeks in magnitude of response across key manifestations of the disease including complete resolution of enthesitis in
The totality of evidence across these two independent datasets of HS and PsA continues to support the hypothesis that the high potency and small molecular size of izokibep can lead to clinically meaningful, differentiated benefits for patients, including resolution of important manifestations of each disease associated with residual pain and severity of disease.
Lonigutamab
As announced in January, we added to our portfolio lonigutamab, an anti-IGF-1R in development for thyroid eye disease (TED), via our acquisition of ValenzaBio. In March we presented at the North American Neuro-Ophthalmology meeting and in May at the Asia-Pacific Orbital Disease and Thyroid Eye Disease Meeting data from the Phase 1 single-ascending dose study in healthy volunteers demonstrating that lonigutamab administered subcutaneously achieved the drug concentration we believe necessary for optimal therapeutic response in TED. A Phase 1/2 Proof-of-Concept (PoC) trial in TED patients is ongoing with subcutaneous administration.
SLRN-517
We also added to our portfolio SLRN-517, a fully human monoclonal antibody targeting c-KIT, via the acquisition of ValenzaBio. This program has now entered the clinic, and a Phase 1/2 PoC trial in healthy volunteers as well as chronic urticaria patients is actively enrolling.
First Quarter 2023 Financial Highlights
Cash Position: Cash and cash equivalents totaled
R&D Expenses: Research and development expenses were
G&A Expenses: General and administrative expenses were
Net Loss: Net loss totaled
About ACELYRIN
ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising product candidates.
About Izokibep
Izokibep is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity, the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody, and an albumin binding domain that results in improved pharmacokinetic (PK) properties. Clinical trial data supports the hypothesis that these unique characteristics of izokibep may provide clinically meaningful and differentiated benefits for patients, including resolution of key manifestations of disease. Izokibep is being evaluated in multiple late-stage trials in moderate-to-severe hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis, with plans to initiate an additional Phase 3 program in axial spondyloarthritis (AxSpA).
Forward Looking Statements
This press release contains forward-looking statements including, but not limited to, statements related to ACELYRIN’s expectations regarding its cash runway and ability to fund anticipated key milestones; the advancement of ACELYRIN’s programs and ability to efficiently deliver on its development plans; the expected timing of development activities including establishment of proof of concept and/or the announcement of clinical data; the therapeutic potential of ACELYRIN’s product candidates including its ability to offer clinically meaningful, differentiated benefits for patients that may include resolution of key manifestations of disease; and other statements that are not historical fact. These forward-looking statements are based on ACELYRIN’s current plans, objectives and projections, and are inherently subject to risks and uncertainties that may cause ACELYRIN’s actual results to materially differ from those anticipated in such forward-looking statements. Such risks and uncertainties include, without limitation, those associated with the successful completion of development and regulatory activities with respect to ACELYRIN’s product candidates; maintaining and defending intellectual property protection; delays or failures to secure adequate supply of its product candidates; ACELYRIN’s failure to realize the expected benefits of its acquisition of ValenzaBio; legal proceedings, government investigations or other actions; macroeconomic conditions; market volatility; and other risks and uncertainties affecting ACELYRIN including those described from time to time under the caption “Risk Factors” and elsewhere in ACELYRIN’s current and future reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. Forward-looking statements contained in this press release are made as of this date, and ACELYRIN undertakes no duty to update such information except as required under applicable law.
| ACELYRIN, INC. | |||||||||
| Consolidated Statements of Operations and Comprehensive Loss | |||||||||
| (in thousands, except share and per share data) | |||||||||
| (unaudited) | |||||||||
| Three Months Ended March 31, | |||||||||
| 2023 | 2022 | ||||||||
| Operating expenses | |||||||||
| Research and development | $ | 167,920 | $ | 13,003 | |||||
| General and administrative | 11,913 | 3,082 | |||||||
| Total operating expenses | 179,833 | 16,085 | |||||||
| Loss from operations | (179,833 | ) | (16,085 | ) | |||||
| Change in fair value of derivative liability | 147 | - | |||||||
| Interest income | 3,299 | - | |||||||
| Other income (expense), net | (63 | ) | - | ||||||
| Net loss | (176,450 | ) | (16,085 | ) | |||||
| Other comprehensive gain (loss) | |||||||||
| Unrealized gain on marketable securities, net | 86 | - | |||||||
| Total other comprehensive gain | $ | 86 | $ | - | |||||
| Net loss and other comprehensive loss | $ | (176,364 | ) | $ | (16,085 | ) | |||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (8.61 | ) | $ | (17.89 | ) | |||
| Weighted-average common shares outstanding, basic and diluted | 20,492,101 | 899,319 | |||||||
| ACELYRIN, INC. | |||||||
| Selected Consolidated Balance Sheet Data | |||||||
| (in thousands) | |||||||
| (unaudited) | |||||||
| March 31, | December 31, | ||||||
| 2023 | 2022 | ||||||
| Cash and cash equivalents | $ | 289,194 | $ | 267,110 | |||
| Total assets | 298,519 | 319,923 | |||||
| Total liabilities | 45,278 | 26,192 | |||||
| Accumulated deficit | (283,528 | ) | (107,078 | ) | |||
